Document

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. [ ]

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes


1	Names of Reporting Persons Samsara BioCapital, L.P.
2	Check the Appropriate Box if a Member of a Group			(a) [ ] (b) [ ]
3	SEC Use Only
4	Source of Funds (See Instructions) OO
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) [ ]
6	Citizenship or Place of Organization Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	Sole Voting Power 0
		8	Shared Voting Power 4,519,361
		9	Sole Dispositive Power 0
		10	Shared Dispositive Power 4,519,361
11	Aggregate Amount Beneficially Owned by Each Reporting Person 4,519,361
12	Check if the Aggregate Amount in Row (11) Excludes Certain Shares [ ]
13	Percent of Class Represented by Amount in Row (11) 11.1%
14	Type of Reporting Person PN


1	Names of Reporting Persons Samsara BioCapital GP, LLC
2	Check the Appropriate Box if a Member of a Group			(a) [ ] (b) [ ]
3	SEC Use Only
4	Source of Funds (See Instructions) OO
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) [ ]
6	Citizenship or Place of Organization Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	Sole Voting Power 0
		8	Shared Voting Power 4,519,361
		9	Sole Dispositive Power 0
		10	Shared Dispositive Power 4,519,361
11	Aggregate Amount Beneficially Owned by Each Reporting Person 4,519,361
12	Check if the Aggregate Amount in Row (11) Excludes Certain Shares [ ]
13	Percent of Class Represented by Amount in Row (11) 11.1%
14	Type of Reporting Person OO (Limited Liability Company)


1	Names of Reporting Persons Srinivas Akkaraju
2	Check the Appropriate Box if a Member of a Group			(a) [ ] (b) [ ]
3	SEC Use Only
4	Source of Funds (See Instructions) OO
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) [ ]
6	Citizenship or Place of Organization USA
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	Sole Voting Power 2,444
		8	Shared Voting Power 4,519,361
		9	Sole Dispositive Power 2,444
		10	Shared Dispositive Power 4,519,361
11	Aggregate Amount Beneficially Owned by Each Reporting Person 4,521,805
12	Check if the Aggregate Amount in Row (11) Excludes Certain Shares [= ]
13	Percent of Class Represented by Amount in Row (11) 11.1%
14	Type of Reporting Person IN

This statement on Schedule 13D (the “Schedule 13D”) relates to the Common Stock, par value $0.0001 per share (“Common Stock”), of Mineralys Therapeutics, Inc., a Delaware corporation (the “Issuer”), whose principal executive offices are located at 150 N. Radnor Chester Road, Suite F200, Radnor, Pennsylvania 19087.

Samsara LP and Samsara LLC are organized under the laws of the State of Delaware. Dr. Akkaraju is a citizen of the United States of America. The Reporting Persons are principally engaged in the business of investing in securities, including of the Issuer. The address of the Reporting Persons is 628 Middlefield Road, Palo Alto, CA 94301.

During the last five years, none of the Reporting Persons (i) has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) were a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Prior to the Issuer’s initial public offering (the “IPO”), Samsara LP acquired preferred shares of the Issuer in a series of financing transactions for aggregate consideration of approximately $24.5 million. In connection with the completion of the IPO, on February 14, 2023, the preferred shares held by Samsara LP automatically converted into 3,581,861 shares of Common Stock.

In addition, on February 9, 2023, the Issuer granted Dr. Akkaraju an option to purchase 44,000 shares of Common Stock at $16.00 per share in consideration for his continued service as a non-employee director of the Issuer. The option vests in 36 monthly installments beginning on March 9, 2023.

Prior to the IPO, the Issuer granted Samsara LP, as well as other holders of the Issuer’s convertible preferred stock and certain holders of its common stock, certain registration rights pursuant to the Amended and Restated Investors’ Rights Agreement, dated June 1, 2022, as amended, by and among the Issuer and the stockholders party thereto (the “Investor Rights Agreement. Specifically the Issuer has granted Samsara LP demand, short-form and piggyback registration rights, which will terminate upon the earlier of (i) five years after the closing of the IPO or (ii) with respect to a particular holder, such time as Rule 144 or another similar exemption under the Securities Act of 1933, as amended, is available for the sale of all shares by such holder without limitation during a three-month period without registration.

The foregoing description of the Investor Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of such agreement filed as an exhibit to this Schedule 13D, and incorporated herein by reference.

In connection with the IPO, the Reporting Persons entered into a letter agreement (the “Lock-Up Agreement”), with the several underwriters for the IPO (the “Underwriters”). Pursuant to the Lock-Up Agreement, the Reporting Persons agreed, without the prior written consent of the Underwriters and subject to limited exceptions, not to offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise dispose of, directly or indirectly, or enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or such other securities for a period of 180 days after the date of the final prospectus used in the IPO (the “Lock-Up Period”).

The foregoing description of the Lock-Up Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of such agreement, the form of which is filed as an exhibit to this Schedule 13D and is incorporated herein by reference.

The Reporting Persons acquired the securities described in this Schedule 13D for investment purposes and intend to review their investments in the Issuer on a continuing basis. Any actions the Reporting Persons might undertake may be made at any time and from time to time without prior notice and will be dependent upon the Reporting Persons’ review of numerous factors, including, but not limited to: an ongoing evaluation of the Issuer’s business, financial condition, operations and prospects; price levels of the Issuer’s securities; general market,

The Reporting Persons may acquire additional securities of the Issuer, or retain or sell all or a portion of the securities then held, in the open market or in privately negotiated transactions. In addition, the Reporting Persons may engage in discussions with management, the Issuer’s board of directors (the “Board”), and securityholders of the Issuer and other relevant parties or encourage, cause or seek to cause the Issuer or such persons to consider or explore extraordinary corporate transactions, such as: a merger, reorganization or other transaction that could result in the de-listing or de-registration of the Common Stock; sales or acquisitions of assets or businesses; changes to the capitalization or distribution policy of the Issuer; or other material changes to the Issuer’s business or corporate structure, including changes in management or the composition of the Board. There can be no assurance, however, that the Reporting Persons will propose such a transaction, that any proposed transaction would receive the requisite approvals from the respective governing bodies and unitholders, as applicable, or that any such transaction would be successfully implemented.

Other than as described above, the Reporting Persons do not currently have any plans or proposals that relate to, or would result in, any of the matters listed in Items 4(a)–(j) of Schedule 13D, although, depending on the factors discussed herein, the Reporting Persons may change their purpose or formulate different plans or proposals with respect thereto at any time.


Reporting Person	Amount beneficially owned	Percent of class:	Sole power to vote or to direct the vote:	Shared power to vote or to direct the vote:	Sole power to dispose or to direct the disposition of:	Shared power to dispose or to direct the disposition of:
Samsara BioCapital, L.P.	4,519,361	11.1%	0	4,519,361	0	4,519,361
Samsara BioCapital GP, LLC	4,519,361	11.1%	0	4,519,361	0	4,519,361
Srinivas Akkaraju	4,521,805	11.1%	2,444	4,519,361	2,444	4,519,361

Samsara LP is the record holder of 4,519,361 shares of Common Stock. Samsara LLC is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP.

Item 4 above summarizes certain provisions of the Investor Rights Agreement and Lock-Up Agreement and is incorporated herein by reference. A copy of each such agreement is attached as an exhibit to this Schedule 13D, and is incorporated herein by reference.

Except as set forth herein, neither the Reporting Persons nor any Related Person has any contracts, arrangements, understandings or relationships (legal or otherwise) with any person with respect to any securities of the Issuer, including but not limited to any contracts, arrangements, understandings or relationships concerning the transfer or voting of such securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies.


Date: February 24, 2023
	SAMSARA BIOCAPITAL, L.P.

	By:	/s/ Abrar Hussain
	Name:	Abrar Hussain
	Title:	Attorney-in-Fact


	SAMSARA BIOCAPITAL GP, LLC

	By:	/s/ Abrar Hussain
	Name:	Abrar Hussain
	Title:	Attorney-in-Fact


	SRINIVAS AKKARAJU, M.D., PH.D.

	By:	/s/ Abrar Hussain
	Name:	Abrar Hussain
	Title:	Attorney-in-Fact


Exhibit Number						Description
1						Joint Filing Agreement.

2						Amended and Restated Investors’ Rights Agreement, dated June 1, 2022, as amended, by and among the Issuer and certain of its stockholders (incorporated by reference to Exhibit 4.2 to the Issuer’s Registration Statement on Form S-1 (File No. 333-269282)).

3						Form of Lock-Up Agreement (incorporated by reference to the Form of Underwriting Agreement filed as Exhibit 1.1 the Issuer’s Registration Statement on Form S-1 (File No. 333-269282)).


CUSIP No. 20451W101			13D			Page 1 of 8 pages


CUSIP No. 20451W101			13D			Page 2 of 8 pages


CUSIP No. 20451W101			13D			Page 3 of 8 pages


CUSIP No. 20451W101			13D			Page 4 of 8 pages